Matches in SemOpenAlex for { <https://semopenalex.org/work/W2796565923> ?p ?o ?g. }
- W2796565923 endingPage "899" @default.
- W2796565923 startingPage "889" @default.
- W2796565923 abstract "Purpose Preoperative chemoradiation therapy (CRT) followed by total mesorectal excision (TME) in locally advanced rectal cancer is the standard of care. To date, the role of consolidation chemotherapy after CRT has rarely been addressed through randomized trials. This study aimed to evaluate the efficacy of CRT followed by consolidation chemotherapy compared with CRT alone. Methods and Materials This study enrolled patients with adenocarcinoma of the rectum and cT3 or cT4 disease with any N category and no metastasis. In arm A (control arm), we planned CRT (50.4 Gy in 28 fractions) with capecitabine followed by TME. In arm B, 2 cycles of capecitabine and oxaliplatin were administered 1 week after the completion of CRT before TME (capecitabine, 1700 mg/m2 per day from day 1 to 14, and oxaliplatin, 100 mg/m2 on day 1, every 3 weeks). The downstaging rate (the proportion of ypT0 to ypT2 and ypN0M0) was the primary endpoint, which was to be tested with a 1-sided type I error of 15% and with 85% power. Results From September 2014 to February 2016, 110 patients (56 in arm A and 54 in arm B) were randomized and 108 (55 in arm A and 53 in arm B) started CRT. TME was conducted per protocol in 96 patients (52 in arm A and 44 in arm B). In arms A and B, downstaging was achieved in 21.2% and 36.4% (P = .077), respectively, and the pathologic complete response rate was 5.8% and 13.6% (P = .167), respectively. Grade ≥3 adverse events occurred in 3.6% of patients in arm A and 9.4% of patients in arm B during the preoperative treatment phase and in 1.9% and 9.0%, respectively, during the postoperative recovery phase. Conclusions Consolidation chemotherapy with 2 cycles of capecitabine and oxaliplatin demonstrated a marginal improvement in the downstaging rate. However, a phase 3 trial of this strategy is discouraged because of the high dropout rate and safety issues. Preoperative chemoradiation therapy (CRT) followed by total mesorectal excision (TME) in locally advanced rectal cancer is the standard of care. To date, the role of consolidation chemotherapy after CRT has rarely been addressed through randomized trials. This study aimed to evaluate the efficacy of CRT followed by consolidation chemotherapy compared with CRT alone. This study enrolled patients with adenocarcinoma of the rectum and cT3 or cT4 disease with any N category and no metastasis. In arm A (control arm), we planned CRT (50.4 Gy in 28 fractions) with capecitabine followed by TME. In arm B, 2 cycles of capecitabine and oxaliplatin were administered 1 week after the completion of CRT before TME (capecitabine, 1700 mg/m2 per day from day 1 to 14, and oxaliplatin, 100 mg/m2 on day 1, every 3 weeks). The downstaging rate (the proportion of ypT0 to ypT2 and ypN0M0) was the primary endpoint, which was to be tested with a 1-sided type I error of 15% and with 85% power. From September 2014 to February 2016, 110 patients (56 in arm A and 54 in arm B) were randomized and 108 (55 in arm A and 53 in arm B) started CRT. TME was conducted per protocol in 96 patients (52 in arm A and 44 in arm B). In arms A and B, downstaging was achieved in 21.2% and 36.4% (P = .077), respectively, and the pathologic complete response rate was 5.8% and 13.6% (P = .167), respectively. Grade ≥3 adverse events occurred in 3.6% of patients in arm A and 9.4% of patients in arm B during the preoperative treatment phase and in 1.9% and 9.0%, respectively, during the postoperative recovery phase. Consolidation chemotherapy with 2 cycles of capecitabine and oxaliplatin demonstrated a marginal improvement in the downstaging rate. However, a phase 3 trial of this strategy is discouraged because of the high dropout rate and safety issues." @default.
- W2796565923 created "2018-04-24" @default.
- W2796565923 creator A5007364197 @default.
- W2796565923 creator A5011928803 @default.
- W2796565923 creator A5012069848 @default.
- W2796565923 creator A5017195273 @default.
- W2796565923 creator A5018855696 @default.
- W2796565923 creator A5026612909 @default.
- W2796565923 creator A5030363363 @default.
- W2796565923 creator A5037183334 @default.
- W2796565923 creator A5044107004 @default.
- W2796565923 creator A5044237346 @default.
- W2796565923 creator A5051992009 @default.
- W2796565923 creator A5057554500 @default.
- W2796565923 creator A5073184597 @default.
- W2796565923 creator A5079274190 @default.
- W2796565923 creator A5084870834 @default.
- W2796565923 date "2018-07-01" @default.
- W2796565923 modified "2023-10-16" @default.
- W2796565923 title "A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03" @default.
- W2796565923 cites W1547839383 @default.
- W2796565923 cites W1826055758 @default.
- W2796565923 cites W1880063947 @default.
- W2796565923 cites W1894792744 @default.
- W2796565923 cites W1902873874 @default.
- W2796565923 cites W1917937632 @default.
- W2796565923 cites W1928621270 @default.
- W2796565923 cites W1968131500 @default.
- W2796565923 cites W1975728816 @default.
- W2796565923 cites W1985380862 @default.
- W2796565923 cites W1999045629 @default.
- W2796565923 cites W2020659765 @default.
- W2796565923 cites W2024035701 @default.
- W2796565923 cites W2042189302 @default.
- W2796565923 cites W2058567407 @default.
- W2796565923 cites W2060239344 @default.
- W2796565923 cites W2097656606 @default.
- W2796565923 cites W2099571006 @default.
- W2796565923 cites W2108051921 @default.
- W2796565923 cites W2112693548 @default.
- W2796565923 cites W2124590938 @default.
- W2796565923 cites W2124695217 @default.
- W2796565923 cites W2125452425 @default.
- W2796565923 cites W2149711218 @default.
- W2796565923 cites W2152671551 @default.
- W2796565923 cites W2160655529 @default.
- W2796565923 cites W2228402821 @default.
- W2796565923 cites W2287854816 @default.
- W2796565923 cites W2492547438 @default.
- W2796565923 cites W2528190341 @default.
- W2796565923 cites W2623754168 @default.
- W2796565923 cites W2687117594 @default.
- W2796565923 cites W2917116917 @default.
- W2796565923 cites W4244315786 @default.
- W2796565923 doi "https://doi.org/10.1016/j.ijrobp.2018.04.013" @default.
- W2796565923 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29976501" @default.
- W2796565923 hasPublicationYear "2018" @default.
- W2796565923 type Work @default.
- W2796565923 sameAs 2796565923 @default.
- W2796565923 citedByCount "39" @default.
- W2796565923 countsByYear W27965659232019 @default.
- W2796565923 countsByYear W27965659232020 @default.
- W2796565923 countsByYear W27965659232021 @default.
- W2796565923 countsByYear W27965659232022 @default.
- W2796565923 countsByYear W27965659232023 @default.
- W2796565923 crossrefType "journal-article" @default.
- W2796565923 hasAuthorship W2796565923A5007364197 @default.
- W2796565923 hasAuthorship W2796565923A5011928803 @default.
- W2796565923 hasAuthorship W2796565923A5012069848 @default.
- W2796565923 hasAuthorship W2796565923A5017195273 @default.
- W2796565923 hasAuthorship W2796565923A5018855696 @default.
- W2796565923 hasAuthorship W2796565923A5026612909 @default.
- W2796565923 hasAuthorship W2796565923A5030363363 @default.
- W2796565923 hasAuthorship W2796565923A5037183334 @default.
- W2796565923 hasAuthorship W2796565923A5044107004 @default.
- W2796565923 hasAuthorship W2796565923A5044237346 @default.
- W2796565923 hasAuthorship W2796565923A5051992009 @default.
- W2796565923 hasAuthorship W2796565923A5057554500 @default.
- W2796565923 hasAuthorship W2796565923A5073184597 @default.
- W2796565923 hasAuthorship W2796565923A5079274190 @default.
- W2796565923 hasAuthorship W2796565923A5084870834 @default.
- W2796565923 hasConcept C121608353 @default.
- W2796565923 hasConcept C126322002 @default.
- W2796565923 hasConcept C141071460 @default.
- W2796565923 hasConcept C168563851 @default.
- W2796565923 hasConcept C203092338 @default.
- W2796565923 hasConcept C2776694085 @default.
- W2796565923 hasConcept C2777201421 @default.
- W2796565923 hasConcept C2777909004 @default.
- W2796565923 hasConcept C2778424827 @default.
- W2796565923 hasConcept C2780962732 @default.
- W2796565923 hasConcept C2781074409 @default.
- W2796565923 hasConcept C526805850 @default.
- W2796565923 hasConcept C71924100 @default.
- W2796565923 hasConceptScore W2796565923C121608353 @default.
- W2796565923 hasConceptScore W2796565923C126322002 @default.
- W2796565923 hasConceptScore W2796565923C141071460 @default.
- W2796565923 hasConceptScore W2796565923C168563851 @default.